Trending...
- Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026
- Pinealage: the app that turns strangers into meditation companions — in crowdfunding phase
- Chicago: Mayor Brandon Johnson, Office Of Reentry Host Holiday Toy Drive For Returning Residents
YANTAI, China, June 5, 2024 ~ At the American Society of Clinical Oncology Annual Meeting (ASCO 2024) held in Chicago from May 31-June 4, 2024, RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, showcased its latest innovations in the field of global cancer treatment. The company presented major research results on its proprietary antibody drug conjugates (ADCs) Disitamab Vedotin (RC48) and RC88.
The innovative drugs were featured in one Clinical Science Symposium, five Poster presentations, and ten online Abstracts at ASCO 2024. These presentations covered multiple cancer types including gastric and bladder cancer, and gynecological tumors. The studies included both monotherapy and combination therapies.
Dr. Jianmin Fang, CEO of RemeGen, expressed his honor at presenting the company's latest research findings on an internationally renowned stage such as ASCO Annual Meeting 2024. He stated that this not only demonstrates RemeGen's leading position in the field of antibody-drug conjugates in China but also proves their commitment to continuing research efforts to provide effective treatment options for patients worldwide.
More on illi News
One of the highlights of RemeGen's presentations was an oral presentation at a Clinical Science Symposium by Professor Song Li from Qilu Hospital of Shandong University. The presentation was based on a randomized, controlled (RCT) multicenter, single-arm, Phase II trial investigating the efficacy of RemeGen's disitamab vedotin (RC48) combined with toripalimab and the oral fluoropyrimidine S-1 in first-line HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma.
In addition to this symposium, RemeGen also presented five posters at ASCO 2024. One of these posters, presented by Professor Sheng Xinan from Peking University Cancer Hospital, focused on the preliminary efficacy and safety results of RC48-C017, a Phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with HER2-expressing muscle-invasive bladder cancer (MIBC). The interim results showed promising efficacy and a manageable safety profile in operable MIBC patients, supporting further investigation for disitamab vedotin plus toripalimab in this population.
More on illi News
Other poster presentations included a Phase II multi-center study on adjuvant or rescue disitamab vedotin (RC48-ADC) for high-risk non-muscle invasive bladder cancer with HER2 expression, and a prospective, single-arm, single-center clinical study on disitamab vedotin combined with toripalimab in patients with advanced penile cancer who have progressed on treatment or are intolerant to cisplatin chemotherapy.
In addition to these presentations, RemeGen also had ten online abstracts accepted by ASCO. These abstracts reflected the results of their RC48 and RC88 drugs in bladder, breast, and GI cancers. This further demonstrates the company's prolific innovation in global cancer treatment.
RemeGen's participation at ASCO 2024 highlights their commitment to advancing cancer treatment options globally. With their innovative drugs and ongoing research efforts, they continue to make significant contributions to the field of oncology.
The innovative drugs were featured in one Clinical Science Symposium, five Poster presentations, and ten online Abstracts at ASCO 2024. These presentations covered multiple cancer types including gastric and bladder cancer, and gynecological tumors. The studies included both monotherapy and combination therapies.
Dr. Jianmin Fang, CEO of RemeGen, expressed his honor at presenting the company's latest research findings on an internationally renowned stage such as ASCO Annual Meeting 2024. He stated that this not only demonstrates RemeGen's leading position in the field of antibody-drug conjugates in China but also proves their commitment to continuing research efforts to provide effective treatment options for patients worldwide.
More on illi News
- Chicago: Mayor Brandon Johnson Signs "Fair Recovery" Executive Order, Prohibiting Sale of Medical Debt, Establishing Responsible Debt Collection Standards
- Guests Can Save 25 Percent Off Last Minute Bookings at KeysCaribbean's Village at Hawks Cay Villas
- Trump's Executive Order Rescheduling Cannabis: Accelerating M&A in a Multibillion-Dollar Industry
- Genuine Hospitality, LLC Selected to Operate Hilton Garden Inn Birmingham SE / Liberty Park
- Documentary "Prescription for Violence: Psychiatry's Deadly Side Effects" Premieres, Exposes Link Between Psychiatric Drugs and Acts of Mass Violence
One of the highlights of RemeGen's presentations was an oral presentation at a Clinical Science Symposium by Professor Song Li from Qilu Hospital of Shandong University. The presentation was based on a randomized, controlled (RCT) multicenter, single-arm, Phase II trial investigating the efficacy of RemeGen's disitamab vedotin (RC48) combined with toripalimab and the oral fluoropyrimidine S-1 in first-line HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma.
In addition to this symposium, RemeGen also presented five posters at ASCO 2024. One of these posters, presented by Professor Sheng Xinan from Peking University Cancer Hospital, focused on the preliminary efficacy and safety results of RC48-C017, a Phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with HER2-expressing muscle-invasive bladder cancer (MIBC). The interim results showed promising efficacy and a manageable safety profile in operable MIBC patients, supporting further investigation for disitamab vedotin plus toripalimab in this population.
More on illi News
- Price Improvement on Luxurious Lāna'i Townhome with Stunning Ocean Views
- Nextvisit Co-Founder Ryan Yannelli Identifies Six Critical Factors for Behavioral Health Providers Evaluating AI Scribes in 2026
- Digi 995 Expands Its Puzzle Lineup With the Release of Digi 995: Word Maze on Mobile Platforms
- CredHub and Real Property Management Join Forces to Empower Franchise Owners with Rental Payment Credit Reporting Solutions
- Leimert Park Announces Weeklong Kwanzaa Festival & Kwanzaa Parade Celebrating Black History, Culture, and Community
Other poster presentations included a Phase II multi-center study on adjuvant or rescue disitamab vedotin (RC48-ADC) for high-risk non-muscle invasive bladder cancer with HER2 expression, and a prospective, single-arm, single-center clinical study on disitamab vedotin combined with toripalimab in patients with advanced penile cancer who have progressed on treatment or are intolerant to cisplatin chemotherapy.
In addition to these presentations, RemeGen also had ten online abstracts accepted by ASCO. These abstracts reflected the results of their RC48 and RC88 drugs in bladder, breast, and GI cancers. This further demonstrates the company's prolific innovation in global cancer treatment.
RemeGen's participation at ASCO 2024 highlights their commitment to advancing cancer treatment options globally. With their innovative drugs and ongoing research efforts, they continue to make significant contributions to the field of oncology.
Filed Under: Business
0 Comments
Latest on illi News
- Christy Sports donates $56K in new gear to SOS Outreach to help kids hit the slopes
- "BigPirate" Sets Sail: A New Narrative-Driven Social Casino Adventure
- Digi 995 Unveils New Official Website and Shop, Expanding the Digiverse
- Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026
- Women's Everyday Safety Is Changing - The Blue Luna Shows How
- Microgaming Unveils Red Papaya: A New Studio Delivering Cutting-Edge, Feature-Rich Slots
- 5-Star Duncan Injury Group Expands Personal Injury Representation to Arizona
- The City of Chicago Will Ring in the New Year with Fireworks on the Chicago River and at Navy Pier Wednesday, December 31
- City of Chicago Shares Key Logistical, Safety Information for Upcoming New Year's Eve Celebration
- The End of "Influencer" Gambling: Bonusetu Analyzes Finland's Strict New Casino Marketing Laws
- AI-Driven Cybersecurity Leader Gains Industry Recognition, Secures $6M Institutional Investment, Builds Momentum Toward $16M Annual Run-Rate Revenue
- TRIO Heating, Air & Plumbing Now Ranks #1 in San Jose
- Milwaukee Job Corps Center Hosts Alumni Day, Calls Alumni to Action on Open Enrollment Campaign
- Kanoa Debuts Gluten-Free Filled Cereals, Delivering Bold Flavor & Better Nutrition for Anytime Snac
- Golden Paper Identifies Global Growth in Packaging Papers and Upgrades Its High-End Production Capacity
- Champagne, Caviar Bumps & Pole Performances — Welcome the New Year Early with HandPicked Social Club
- A New Soul Album: Heart Of Kwanzaa, 7-Day Celebration
- Allegiant Management Group Named 2025 Market Leader in Orlando by PropertyManagement.com
- National Van Lines Delivers Holiday Cheer with Aspire Partnership
- NAFMNP Awarded USDA Cooperative Agreement to Continue MarketLink Program Under FFAB